Thousands of blood cancer patients in England have been designed to benefit from a groundbreaking treatment that targets and destroys cancer cells from within, earning it the nickname of “Trojan Horse” drug.

In the first of the world, the UK National Health Services (NHS) – will offer the country’s healthcare – treatment, Belontmab Mafodotin, about 1,500 people every year are struggling with many myeloma, a aggressive and currently incurable form of blood cancer.

The National Institute for Health and Care Excellence (NICE) took a decision after approved the drug under the new guidance issued on Friday. Approval is one step ahead in cancer care, especially for patients whose disease has moved forward despite standard treatment.

“Myeloma is an aggressive type of blood cancer, but we have seen a stable improvement in the approach for patients in recent years because we have introduced new targeted remedies. I am glad that patients in England will be the first to benefit from this new treatment, who have the ability to keep cancer in the Gulf for years.”

What is “Trojan Horse” medicine?

Also marketed as Belanrep Belantamab Mafodotin is a form of target antibody therapy.

Unlike traditional chemotherapy, which affects both healthy and cancer cells, this drug is only designed to find, enter and destroy cancer cells.

This Trojan acts like an ancient story of a horse. The drug is “secret” in the cancer cell by connecting a specific protein found on the surface. Once inside, it releases a powerful toxin that kills the cell from the vicinity, without damaging the surrounding healthy tissue.

Along with other cancer drugs -administered through a infusion every three weeks, BelontmaB mafodotin has shown promising results in tests.

When combined with bortezomib and dexamethasone, it delayed the progression of cancer at an average of three years. In contrast, patients usually such as darutumbeb have usually experience the progression of the disease within a year.

Is this a game changer for patients?

For people like Paul Sylvester, a 60 -year -old man from Sheffield was diagnosed in 2023, new drug life is about to change life.

“I think this treatment has brought back the balloon of the party to the house. It’s amazing – within the first two or three weeks, after the first dose, I was in a discount,” he said.

Sylvester received the drug through an initial access program at the Royal Hallmashire Hospital after failing to prevent cancer.

Doctors believe that therapy is especially promised for patients who have abolished other treatment options. It will be introduced to those whose illness has progressed or has failed to respond to the first row treatments.

Future of treatment of blood cancer

Patient advocacy groups have also welcomed development. Shelagh McKinley, director of research and advocacy at Myloma UK, said the approval was a major victory.

“We are working very hard for the previous year to approve this treatment and we know it will change the lives of thousands of people with myeloma,” he said.

Health Minister Karin Smith said that by embracing state -of -the -art “Trojan Horse” technology, NHS is providing new hope to blood cancer patients across the country.

As the research continues and more data emerges, Bellantamba mafodotine may change how blood cancer such as myeloma is treated in the coming years.